{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:17:29Z","timestamp":1785802649572,"version":"3.56.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018679","name":"HLS Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018679","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015070","name":"Department of Psychiatry, University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014405","name":"Centre for Addiction and Mental Health Foundation","doi-asserted-by":"publisher","award":["080\/2021"],"award-info":[{"award-number":["080\/2021"]}],"id":[{"id":"10.13039\/100014405","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003579","name":"University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003579","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.schres.2024.01.021","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T17:31:49Z","timestamp":1705944709000},"page":"451-456","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Safety of BEN guidelines in clozapine treatment: A Canadian perspective"],"prefix":"10.1016","volume":"264","author":[{"given":"Sally","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Araba","family":"Chintoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Alarabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri Mahavir","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Remington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.schres.2024.01.021_bb0005","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJM199307153290303","article-title":"Clozapine-induced agranulocytosis. Incidence and risk factors in the United States","volume":"329","author":"Alvir","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.schres.2024.01.021_bb0010","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.schres.2022.02.009","article-title":"Re-examining the utility and validity of benign ethnic neutropenia: a narrative literature review","volume":"253","author":"Andreou","year":"2023","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2024.01.021_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.06.003","article-title":"Benign ethnic neutropenia","volume":"37","author":"Atallah-Yunes","year":"2019","journal-title":"Blood Rev."},{"issue":"4","key":"10.1016\/j.schres.2024.01.021_bb0020","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1192\/bjp.169.4.483","article-title":"Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland","volume":"169","author":"Atkin","year":"1996","journal-title":"Br. J. Psychiatry"},{"issue":"11","key":"10.1016\/j.schres.2024.01.021_bb0025","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1056\/NEJM199103143241107","article-title":"Clozapine. A novel antipsychotic agent","volume":"324","author":"Baldessarini","year":"1991","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.schres.2024.01.021_bb0030","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/JCP.0000000000000478","article-title":"Clozapine underutilization in the treatment of schizophrenia: how can clozapine prescription rates be improved?","volume":"36","author":"Bogers","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"issue":"25","key":"10.1016\/j.schres.2024.01.021_bb0035","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1056\/NEJM196612222752504","article-title":"Leukopenia in Negroes","volume":"275","author":"Broun","year":"1966","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.schres.2024.01.021_bb0040","article-title":"Compendium of pharmaceuticals and specialties 2022","volume":"2022","author":"Canadian Pharmacists Association","year":"2022","journal-title":"Canadian Pharmacists Association"},{"issue":"6","key":"10.1016\/j.schres.2024.01.021_bb0045","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1111\/ijlh.12712","article-title":"Duffy null genotype or Fy(a-b-) phenotype are more accurate than self-declared race for diagnosing benign ethnic neutropenia in Brazilian population","volume":"39","author":"Dinardo","year":"2017","journal-title":"Int. J. Lab. Hematol."},{"issue":"2","key":"10.1016\/j.schres.2024.01.021_bb0050","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1176\/appi.ps.202000681","article-title":"Race-based medicine, clozapine, and benign (ethnic) neutropenia: a call for nuance","volume":"72","author":"Dotson","year":"2021","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.schres.2024.01.021_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2020.113644","article-title":"A commentary on improving clozapine accessibility and reducing treatment cost","volume":"296","author":"Gurrera","year":"2021","journal-title":"Psychiatry Res."},{"issue":"1","key":"10.1016\/j.schres.2024.01.021_bb0060","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/lc.1999.v133.a94931","article-title":"Benign ethnic neutropenia: what is a normal absolute neutrophil count?","volume":"133","author":"Haddy","year":"1999","journal-title":"J. Lab. Clin. Med."},{"issue":"Suppl. 3","key":"10.1016\/j.schres.2024.01.021_bb0065","first-page":"3","article-title":"Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry","volume":"59","author":"Honigfeld","year":"1998","journal-title":"J. Clin. Psychiatry"},{"issue":"8","key":"10.1016\/j.schres.2024.01.021_bb0070","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1176\/ps.46.8.801","article-title":"Effects of stringent criteria on eligibility for clozapine among public mental health clients","volume":"46","author":"Juarez-Reyes","year":"1995","journal-title":"Psychiatr. Serv."},{"issue":"9","key":"10.1016\/j.schres.2024.01.021_bb0075","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.4088\/JCP.v67n0911","article-title":"Clozapine utilization and outcomes by race in a public mental health system: 1994-2000","volume":"67","author":"Kelly","year":"2006","journal-title":"J. Clin. Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2024.01.021_bb0080","doi-asserted-by":"crossref","first-page":"e909","DOI":"10.4088\/JCP.15r10085","article-title":"Benign ethnic neutropenia and clozapine use: a systematic review of the evidence and treatment recommendations","volume":"77","author":"Manu","year":"2016","journal-title":"J. Clin. Psychiatry"},{"issue":"8","key":"10.1016\/j.schres.2024.01.021_bb0085","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1177\/0269881115576688","article-title":"Treatment resistant or resistant to treatment? Antipsychotic plasma levels in patients with poorly controlled psychotic symptoms","volume":"29","author":"McCutcheon","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.schres.2024.01.021_bb0090","article-title":"The clozapine handbook","author":"Meyer","year":"2019","journal-title":"Cambridge University Press"},{"issue":"11","key":"10.1016\/j.schres.2024.01.021_bb0095","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1007\/s00277-020-04215-y","article-title":"Clozapine-induced agranulocytosis","volume":"99","author":"Mijovic","year":"2020","journal-title":"Ann. Hematol."},{"issue":"6","key":"10.1016\/j.schres.2024.01.021_bb0100","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1056\/NEJM197608052950602","article-title":"The resistance factor to plasmodium vivax in blacks. The Duffy-blood-group genotype","volume":"295","author":"Miller","year":"1976","journal-title":"FyFy. N Engl J Med"},{"issue":"2","key":"10.1016\/j.schres.2024.01.021_bb0105","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/acps.12898","article-title":"Meta-analysis examining the epidemiology of clozapine-associated neutropenia","volume":"138","author":"Myles","year":"2018","journal-title":"Acta Psychiatr. Scand."},{"issue":"5","key":"10.1016\/j.schres.2024.01.021_bb0110","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/0004867419833166","article-title":"A meta-analysis of controlled studies comparing the association between clozapine and other antipsychotic medications and the development of neutropenia","volume":"53","author":"Myles","year":"2019","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.schres.2024.01.021_bb0115","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.neubiorev.2020.01.017","article-title":"Demographic and clinical features as predictors of clozapine response in patients with schizophrenia spectrum disorders: a systematic review and meta-analysis","volume":"111","author":"Okhuijsen-Pfeifer","year":"2020","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"4","key":"10.1016\/j.schres.2024.01.021_bb0120","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/schbul\/sbab006","article-title":"There is life after the UK clozapine central non-Rechallenge database","volume":"47","author":"Oloyede","year":"2021","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.schres.2024.01.021_bb0125","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1186\/s12888-021-03514-6","article-title":"Benign ethnic neutropenia: an analysis of prevalence, timing and identification accuracy in two large inner-city NHS hospitals","volume":"21","author":"Oloyede","year":"2021","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.schres.2024.01.021_bb0130","doi-asserted-by":"crossref","DOI":"10.1017\/S204579602200066X","article-title":"Clozapine haematological monitoring for neutropenia: a global perspective","volume":"31","author":"Oloyede","year":"2022","journal-title":"Epidemiol. Psychiatr. Sci."},{"issue":"1","key":"10.1016\/j.schres.2024.01.021_bb0135","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000367962","article-title":"Genome-wide association studies in Africans and African Americans: expanding the framework of the genomics of human traits and disease","volume":"18","author":"Peprah","year":"2015","journal-title":"Public Health Genomics"},{"issue":"959","key":"10.1016\/j.schres.2024.01.021_bb0140","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/pgmj.2004.031161","article-title":"Clozapine, agranulocytosis, and benign ethnic neutropenia","volume":"81","author":"Rajagopal","year":"2005","journal-title":"Postgrad. Med. J."},{"issue":"1","key":"10.1016\/j.schres.2024.01.021_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000360","article-title":"Reduced neutrophil count in people of African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines gene","volume":"5","author":"Reich","year":"2009","journal-title":"PLoS Genet."},{"issue":"3","key":"10.1016\/j.schres.2024.01.021_bb0150","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/070674379604100306","article-title":"Clozapine: current status and role in the pharmacotherapy of schizophrenia","volume":"41","author":"Remington","year":"1996","journal-title":"Can. J. Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2024.01.021_bb0155","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1177\/0706743717720448","article-title":"Guidelines for the pharmacotherapy of schizophrenia in adults","volume":"62","author":"Remington","year":"2017","journal-title":"Can. J. Psychiatry"},{"issue":"11","key":"10.1016\/j.schres.2024.01.021_bb0160","doi-asserted-by":"crossref","first-page":"e1454","DOI":"10.4088\/JCP.15m10315","article-title":"Evaluation of the safety of clozapine use in patients with benign neutropenia","volume":"77","author":"Richardson","year":"2016","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2024.01.021_bb0165","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1056\/NEJM197801262980402","article-title":"Effect of lithium on neutrophil mass and production","volume":"298","author":"Rothstein","year":"1978","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.schres.2024.01.021_bb0170","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-0609.1988.tb01192.x","article-title":"Benign familial leukopenia and neutropenia in different ethnic groups","volume":"41","author":"Shoenfeld","year":"1988","journal-title":"Eur. J. Haematol."},{"issue":"6","key":"10.1016\/j.schres.2024.01.021_bb0175","doi-asserted-by":"crossref","first-page":"809","DOI":"10.7326\/0003-4819-88-6-809_2","article-title":"Lithium-induced granulocytosis","volume":"88","author":"Stein","year":"1978","journal-title":"Ann. Intern. Med."},{"issue":"6","key":"10.1016\/j.schres.2024.01.021_bb0180","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1177\/0269881110364267","article-title":"The importance of the recognition of benign ethnic neutropenia in black patients during treatment with clozapine: case reports and database study","volume":"25","author":"Whiskey","year":"2011","journal-title":"J. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.schres.2024.01.021_bb0185","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/YIC.0000000000000258","article-title":"Need to bleed? Clozapine haematological monitoring approaches a time for change","volume":"34","author":"Whiskey","year":"2019","journal-title":"Int. Clin. Psychopharmacol."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996424000215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996424000215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T01:46:50Z","timestamp":1724723210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996424000215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":37,"alternative-id":["S0920996424000215"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2024.01.021","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of BEN guidelines in clozapine treatment: A Canadian perspective","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2024.01.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}